Previous 10 | Next 10 |
2023-08-14 17:39:02 ET SCYNEXIS press release ( NASDAQ: SCYX ): Q2 GAAP EPS of $2.46 beats by $1.01 . Revenue of $131.5M (+9862.1% Y/Y) beats by $36.1M . Shares +2.14% AH. For further details see: SCYNEXIS GAAP EPS of $2.46 beats by $1.01, revenue...
SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME ® (Ibrexafungerp Tablets). SCYNEXIS received an upfront payment of $90 million upon deal close. SCYNEXIS announced the achievement of the first development milestone of $25 million under the exclu...
JERSEY CITY, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that China’s National Medical Products Administration (NMPA)...
2023-06-21 12:15:22 ET New Jersey-based biotech Scynexis ( NASDAQ: SCYX ) announced Wednesday that it achieved a performance-based milestone payment worth $25M from its partner GSK ( NYSE: GSK ) over its studies into antifungal agent ibrexafungerp. The payment comes afte...
JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the achievement of a $25 million performance-based development mile...
JERSEY CITY, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that David Angulo, President and Chief Executive Officer, will take...
2023-05-21 04:41:46 ET Summary With their first product approval last quarter, Europe should follow suit. Their U.S. partner is experienced in commercializing antibiotics. Their second drug candidate is likely to succeed in Phase 2. Cidara Therapeutics ( CDTX ) i...
2023-05-19 16:57:45 ET Summary SCYX's 1Q23 earnings highlights steadily underwhelming ibrexafungerp sales, with substantial growth expected in 2024/2025 once GSK begins promotion. Phase 3 MARIO trial data, pivotal for potential label expansion, is anticipated in 1H'24. The study f...
Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C. auris is becoming a major public health threat and is found in over 3...
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and tiered royalties. GSK obtains the exclusive rights to ibrexafungerp; SCYNEXIS retains rights to all other assets in its proprietary class of enfumafungin-derived ...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...